We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
HASO | Hastings Technology Metals Limited | 0.035 | 0.019 | 118.75% | 4,631 | 2 |
ZEUO | Zeus Resources Limited | 0.002 | 0.001 | 100.00% | 50,000 | 1 |
IPTOB | Impact Minerals Ltd | 0.002 | 0.001 | 100.00% | 500,000 | 1 |
RC1O | Redcastle Resources Ltd | 0.002 | 0.001 | 100.00% | 5,000,000 | 1 |
GTI | Gratifii Limited | 0.011 | 0.004 | 57.14% | 11,218,173 | 20 |
RCR | Rincon Resources Limited | 0.15 | 0.054 | 56.25% | 39,665,132 | 959 |
PL3O | Patagonia Lithium Ltd | 0.017 | 0.006 | 54.55% | 330,000 | 3 |
SRNOD | Surefire Resources NL | 0.003 | 0.001 | 50.00% | 167,333 | 1 |
BUYO | Bounty Oil & Gas | 0.003 | 0.001 | 50.00% | 1,183,332 | 3 |
ADG | Adelong Gold Limited | 0.004 | 0.001 | 33.33% | 116,333 | 2 |
EDE | Eden Innovations Ltd | 0.002 | 0.0005 | 33.33% | 1,734,954 | 8 |
--Advisory Board to Provide Guidance for Company's Eosinophilic Esophagitis Clinical Program-- VICTORIA, BC, May 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the formation of a Clinical Advisory Board for its gastrointestinal ("GI") program. The Clinical Advisory Board is comprised of Dr. Evan Dellon (Chairman), Dr. Stephen Attwood, Dr. Albert Bredenoord, Dr. Donna Griebel, Dr. Ikuo Hirano and Dr. Roos Pouw. The Clinical Advisory Board will work closely with Eupraxia as it continues ...
Spirent Communications plc (LSE:SPT), the leading provider of test and assurance solutions for next-generation devices and networks, today announced PNT X, its next-generation positioning, navigation and timing (PNT) simulation system. Designed to deliver unprecedented performance and flexibility in PNT simulation and testing, PNT X offers the highest fidelity and most signal sources in a single test platform to address the future of enhanced autonomy, safety, efficiency, and precision.
Marin Software Incorporated (NASDAQ: MRIN) (“Marin”, “Marin Software” or the “Company”), a leading provider of digital marketing software for performance-driven advertisers and agencies, today announced financial results for the first quarter ended March 31, 2024.
Usio, Inc. (NASDAQ: USIO), a leading FinTech company that operates a full stack, cloud-based payment platform supporting integrated acceptance and card issuing solutions, provides the following update on its partnership with MOBILEMONEY. A trailblazer in the mobile financial services industry, MOBILEMONEY provides kiosks, hardware, software, installation, on-site training, cash management, and back-end administrative support to a variety of markets including convenience stores, special events, gaming facilities, hospitality, and other businesses throughout the country. Their experience and client base demonstrate Usio’s commitment and ability to support unique financial solutions that serve specialized markets.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 60,274.00 | 1,152.80 | 1.95% | 1.16T | 4,706,010,653 |
ETH | Ethereum | 3,028.87 | 41.79 | 1.40% | 358.36B | 2,125,268,824 |
USDT | Tether USD | 0.99982 | -0.00016 | -0.02% | 97.83B | 309,636,718 |
BNB | Binance Coin | 568.82 | 8.23 | 1.47% | 88.7B | 212,223,713 |
SOL | Solana | 140.40 | 2.73 | 1.98% | 60.64B | 1,236,988,268 |
STETH | stETH | 3,013.79 | 34.18 | 1.15% | 29.02B | 26,276,844 |
XRP | Ripple | 0.5216 | 0.0036 | 0.69% | 28.22B | 309,599,217 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 1,181,787,539 |
DOGE | Dogecoin | 0.1356 | 0.00353 | 2.67% | 19.05B | 439,427,809 |
TONCOIN | Wrapped TON Coin | 5.41 | 0.257653 | 5.01% | 18.24B | 102,132,895 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions